Skip to content
Aperlena

Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

Awarded Contract award

Key facts

Buyer
NHS England
Where
United Kingdom
Procedure
Open procedure Anyone may submit a bid, in one step, with no pre-selection. Full entry
CPV code The EU's common vocabulary for what is being bought: an eight-digit code every notice carries. Full entry
85100000 Health services
Original language
English
Source
via Find a Tender Service (UK Cabinet Office / Crown Commercial Service), verified 1 week ago
Watch this tender

Bidding is closed. An award or a correction on this notice: an email when the register sees it. Log in

  1. Published
  2. Awarded pending

Summary

Machine-generated summary

NHS England has awarded contracts for the Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service and the Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service. These are one-time in vivo gene replacement therapies for spinal muscular atrophy, delivered intravenously to babies aged 12 months and under, and by intrathecal injection to patients aged 2 years and over, subject to NICE technology appraisal with expected final guidance in late 2026. The procurement was carried out in lots. The winners are Alder Hey Children's NHS FT, Great Ormond Street Hospital, Guy's and St Thomas' NHS Foundation Trust, King's College Hospital NHS FT, Leeds Teaching Hospitals NHS Foundation Trust, North Manchester General Hospital, Northern Care Alliance NHS Foundation Trust and Oxford University Hospitals NHS FT. Contract values are estimated and depend on the number of patients treated.

Description

Intention to award the Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service. This is a a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA. Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026. Procurement was carried out in Lots for the services as detailed above. Contract values are estimated and will be dependent on number of patients actually treated at each awarded provider.

Official source

Source: Find a Tender Service (UK Cabinet Office / Crown Commercial Service)

Always verify details on the official notice.

Report an error in this notice

Last verified against Find a Tender Service (UK Cabinet Office / Crown Commercial Service) 1 week ago

Documents on Find a Tender Service (UK Cabinet Office / Crown Commercial Service) (English)

More from this buyer

Full buyer profile

25 open tenders right now

Recent awards

Similar tenders

Market context

Avg. open tender · Health & social work
€38,851,714
2,073 open across Europe right now
Buyer track record on Aperlena
235 notices tracked · 169 awarded
€407,038,929 in awarded contracts

Never miss a tender like this

110 new notices in Health & social work in United Kingdom in the last 7 days. Get an email when new ones appear. Free.

Set up my alert

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Search from any page
Ctrl K
Search from any page
?
Show these shortcuts
Esc
Close

Index

Close
Log in

Language